Bioline Rx Ltd ADR (NASDAQ:BLRX) does about 606.69K shares in volume on a normal day but saw 36518744 shares change hands in the recent trading day. The company now has a market cap of 19.53M USD. Its current market price is $5.25, marking an increase of 38.49% compared to the previous close of $3.79. The 52 week high reached by this stock is $35.60 whilst the lowest price level in 52 weeks is $2.30.
The consensus objective for the share price is $26.00, suggesting that the stock has a potential upside of 79.81% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 18, 2017 when Maxim Group upgraded the stock to “Buy” and issued a price target of between $1 and $3. Maxim Group downgraded its price target at $4-$1.
The current price level is 50.71%, 64.18%, and -52.75% away from its SMA20, SMA50, and SMA200 respectively, with the BLRX price moving below the 50-day SMA on current market day. Bioline Rx Ltd ADR (BLRX) stock is up 38.16% over the week and 51.30% over the past month. Its price is -38.67% year-to-date and -81.75% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.53 and -0.28 for whole year. Expected sales for next quarter are $776.67k, which analysts say will come at $2.58M for the current fiscal year and next year at $7.27M. In addition, estimates put the company’s current quarterly revenue at an average of $661.33k.
To reach the target analysts have set, the stock logically needs to grow 79.81 percent from here.
Outstanding shares total 3.72M with insiders holding 4.67% of the shares and institutional holders owning 0.25% of the company’s common stock. The company has a return on investment of -11.53% and return on equity of -20.03%. The beta has a value of 1.29. Price to book ratio is 0.94 and price to sales ratio is 0.87.
